Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Inclusion Criteria: * Patients must have histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is unresectable or metastatic. * Patients must have received at least one prior chemotherapy regimen for unresectable/ metastatic disease. There is no limit to number of prior regimens. Prior erlotinib therapy is allowed. * Minimum of two weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy. Patients must have recovered from the acute toxicities of any prior therapy to NIH-NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 \</= Grade 1. * Age \>/= 18 years. Because no dosing or adverse event data are currently available on the use of erlotinib administered in combination with RAD001 in patients \< 18 years of age, children are excluded from this study. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Patients must have at least one measurable site of disease according to Response Evaluation Criteria In Solid Tumors (RECIST). This site must be outside a radiation field. * Adequate hematologic, hepatic and renal parameters: leukocytes =/\>3,000/ul, absolute neutrophil count =/\>1,500/ul, platelets =/\>100,000/ul, hemoglobin =/\>9g/dL, total bilirubin \</= 1.5 mg/dl, aspartate aminotransferase (AST) \</=230 and alanine aminotransferase (ALT) \</=280 IU/L for subjects with documented liver metastases; AST \</=115 and ALT \</=140 IU/L for subjects without evi…